ST8SIA1 encodes an alpha-2,8-sialyltransferase that catalyzes the addition of sialic acid residues to gangliosides, converting GM3 to GD3 and enabling synthesis of complex polysialylated gangliosides 12. This enzyme is a membrane-bound glycosyltransferase located in the Golgi apparatus involved in glycosphingolipid biosynthesis. In cancer biology, ST8SIA1 plays a critical oncogenic role. Its expression correlates with ganglioside GD2 production and breast cancer stem cell function, activating FAK-AKT-mTOR signaling to promote tumor growth and metastasis in triple-negative breast cancer 3. ST8SIA1 overexpression drives colorectal cancer progression through altered sialylation patterns and chemoresistance, while miR-33a and let-7e suppress CRC by targeting ST8SIA1 4. In neuroblastoma, mesenchymal transition reduces ST8SIA1 expression and GD2 synthesis, conferring resistance to anti-GD2 immunotherapy, which can be reversed by EZH2 inhibition 5. Paradoxically, ST8SIA1 overexpression in rectal adenocarcinoma inhibits tumor progression by suppressing TGF-β1 signaling and enhancing CD8+ T cell cytotoxicity 6. Beyond cancer, ST8SIA1 contributes to rheumatoid arthritis pathogenesis 7 and thyroid-associated ophthalmopathy severity through functional promoter variants 8. Recent evidence identifies ST8SIA1-mediated GD3 production as a novel senescence marker in osteoarthritis 9.